Evidence map›Paper›PMID 40452058›Full record

ArticleEuropean journal of medical research2025

Estimated glucose disposal rate and the risk of major adverse cardio-cerebrovascular outcomes and mortality in patients undergoing percutaneous coronary intervention: a retrospective cohort study.

Shayan Shojaei, Asma Mousavi, Alireza Arzhangzadeh, Dorsa Salabat, Seyed Morteza Pourfaraji, Fatemeh Ojaghi Shirmard, Hamidreza Soleimani, Ramtin Khanipour, Haleh Ashraf, Farzad Masoudkabir and 5 more

Abstract read
In one paragraph

Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shayan ShojaeiCardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Asma MousaviCardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Alireza ArzhangzadehDepartment of Cardiology, Shiraz University of Medical Sciences, Shiraz, Iran.
Dorsa SalabatCardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Morteza PourfarajiCardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Fatemeh Ojaghi ShirmardCardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Hamidreza SoleimaniCardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Ramtin KhanipourDepartment of Internal Medicine and Cardiology, University of South Florida-HCA, Bayonet Point Hospital, Hudson, FL, USA.
Haleh AshrafCardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Farzad MasoudkabirCardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Jaime P AlmandozDepartment of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, TX, USA.
John R NelsonDirector at California Cardiovascular Institute, Fresno, CA, USA.
Harrison AnilFlorida West Primary Care Institute, Pensacola, FL, USA.
Wilbert AronowCardiology Division, Westchester Medical Center, New York Medical College, Valhalla, NY, USA.
Kaveh HosseiniCardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. kaveh_hosseini130@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile percutaneous coronary intervention (PCI) has improved survival rates, many patients remain at risk for future adverse cardio-cerebral events. This study explores the role of insulin resistance, measured by the estimated glucose disposal rate (eGDR), as a potential predictor of cardio-cerebrovascular outcomes and mortality.

methodsThis retrospective analysis included patients who underwent PCI at our center between 2015 and 2020. Patients were categorized by glycemic status into individuals with diabetes (DM), pre-DM and normal glucose levels. Our primary outcome was major adverse cardiac and cerebrovascular event (MACCE).

resultsWe included 2144 patients-236 patients with pre-DM, 1735 with DM, and 173 with normal glucose levels. After a mean follow-up of 550 days, patients with pre-DM in the Q3 and Q4 quartiles of eGDR were less likely to experience MACCE (HR: 0.172, 95% CI 0.036-0.813 and HR: 0.096, 95% CI 0.013-0.713, respectively). In the DM and non-DM groups, there was no significant relationship between eGDR and MACCE. After adjustment for lipid profile and history of statin medication, results remained consistent for both Q3 and Q4 in pre-DM subgroup with lower rate of MACCE (HR: 0.168, 95% CI 0.033-0.820) and (HR: 0.099, 95% CI 0.012-0.814). Additionally, the Q4 compared to Q1 in the non-DM group demonstrated significantly lower MACCE (HR: 0.000, 95% CI 0.000-0.759).

conclusionsOur findings suggest that eGDR could be an important tool for assessing risk for future cardio-cerebral events and mortality in patients with pre-DM and normal glycemic levels who undergo PCI. However, its predictive power in patients with DM appears to be limited.

Indexed as

Blood GlucoseCardiovascular DiseasesCerebrovascular DisordersPercutaneous Coronary InterventionAgedDiabetes MellitusFemaleHumansInsulin ResistanceMaleMiddle AgedRetrospective StudiesRisk FactorsBlood GlucoseEstimated glucose disposal rateMajor adverse cardio-cerebrovascular outcomesMortalityPercutaneous coronary intervention

Identifiers

PMID40452058
PMCPMC12128272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.